Research Analysts Issue Forecasts for AGIO FY2025 Earnings

Key Points

• HC Wainwright has revised its FY2025 earnings per share (EPS) estimate for Agios Pharmaceuticals to ($7.68), down from a previous estimate of ($7.62), while maintaining a "Buy" rating with a target price of $56.00.
• The company's last quarterly earnings report showed an EPS of ($1.93), which missed the consensus estimate of ($1.74) by ($0.19), despite outperforming revenue expectations.
• Insider sales have occurred, with CEO Brian Goff selling 11,085 shares recently, indicating potential shifts in ownership dynamics as insiders have sold a total of 57,448 shares over the last 90 days.

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO - Free Report) - Investment analysts at HC Wainwright cut their FY2025 earnings estimates for Agios Pharmaceuticals in a research report issued on Thursday, September 4th. HC Wainwright analyst E. Bodnar now expects that the biopharmaceutical company will earn ($7.68) per share for the year, down from their prior forecast of ($7.62). HC Wainwright currently has a "Buy" rating and a $56.00 target price on the stock. The consensus estimate for Agios Pharmaceuticals' current full-year earnings is ($6.85) per share. HC Wainwright also issued estimates for Agios Pharmaceuticals' Q4 2025 earnings at ($2.06) EPS and FY2029 earnings at ($6.50) EPS.

A number of other research analysts also recently weighed in on AGIO. Scotiabank lowered their price objective on shares of Agios Pharmaceuticals from $71.00 to $65.00 and set a "sector outperform" rating on the stock in a research report on Monday, July 28th. Bank of America lowered their price objective on shares of Agios Pharmaceuticals from $52.00 to $51.00 and set a "buy" rating on the stock in a research report on Tuesday, July 22nd. Finally, Wall Street Zen downgraded shares of Agios Pharmaceuticals from a "hold" rating to a "sell" rating in a research report on Monday, May 19th. Six analysts have rated the stock with a Buy rating and two have issued a Hold rating to the stock. According to data from MarketBeat, Agios Pharmaceuticals presently has a consensus rating of "Moderate Buy" and a consensus price target of $56.00.

Agios Pharmaceuticals Stock Performance

Shares of NASDAQ:AGIO traded up $0.28 during trading on Monday, reaching $36.78. 603,418 shares of the stock traded hands, compared to its average volume of 751,284. The stock has a market cap of $2.14 billion, a P/E ratio of 3.34 and a beta of 0.87. The stock has a 50-day moving average of $37.71 and a two-hundred day moving average of $33.26. Agios Pharmaceuticals has a 52-week low of $23.42 and a 52-week high of $62.58.

Agios Pharmaceuticals (NASDAQ:AGIO - Get Free Report) last posted its quarterly earnings results on Thursday, July 31st. The biopharmaceutical company reported ($1.93) EPS for the quarter, missing analysts' consensus estimates of ($1.74) by ($0.19). Agios Pharmaceuticals had a net margin of 1,590.42% and a negative return on equity of 3.49%. The firm had revenue of $12.50 million for the quarter, compared to analysts' expectations of $9.46 million.

Hedge Funds Weigh In On Agios Pharmaceuticals

A number of institutional investors and hedge funds have recently made changes to their positions in the business. Hudson Bay Capital Management LP grew its stake in shares of Agios Pharmaceuticals by 17.4% in the 2nd quarter. Hudson Bay Capital Management LP now owns 130,000 shares of the biopharmaceutical company's stock worth $4,324,000 after buying an additional 19,280 shares in the last quarter. Headlands Technologies LLC lifted its holdings in shares of Agios Pharmaceuticals by 18.0% in the 2nd quarter. Headlands Technologies LLC now owns 12,644 shares of the biopharmaceutical company's stock worth $421,000 after acquiring an additional 1,929 shares during the last quarter. Tower Research Capital LLC TRC lifted its holdings in shares of Agios Pharmaceuticals by 634.3% in the 2nd quarter. Tower Research Capital LLC TRC now owns 6,440 shares of the biopharmaceutical company's stock worth $214,000 after acquiring an additional 5,563 shares during the last quarter. Two Sigma Securities LLC bought a new stake in shares of Agios Pharmaceuticals in the 2nd quarter worth about $288,000. Finally, Moore Capital Management LP lifted its holdings in shares of Agios Pharmaceuticals by 33.3% in the 2nd quarter. Moore Capital Management LP now owns 80,000 shares of the biopharmaceutical company's stock worth $2,661,000 after acquiring an additional 20,000 shares during the last quarter.

Insider Transactions at Agios Pharmaceuticals

In related news, Director David Scadden sold 1,400 shares of the firm's stock in a transaction on Thursday, July 10th. The shares were sold at an average price of $40.00, for a total transaction of $56,000.00. Following the completion of the transaction, the director directly owned 17,603 shares of the company's stock, valued at approximately $704,120. This trade represents a 7.37% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Sarah Gheuens sold 11,914 shares of the firm's stock in a transaction on Wednesday, July 9th. The shares were sold at an average price of $37.99, for a total transaction of $452,612.86. Following the transaction, the insider directly owned 61,271 shares of the company's stock, valued at $2,327,685.29. The trade was a 16.28% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders sold 65,994 shares of company stock valued at $2,341,232. Company insiders own 4.30% of the company's stock.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.